RxDoctor Payments Data

Maria Vega-Martinez, MD

Pulmonary Disease · Humacao, PRNPI 1497956890

Payments from drug & device makers

$919in general payments, 2019–2025

Across 30 payments — averaging $30.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$156
  • Medtronic$125
  • Sanofi$121
  • Actelion Pharmaceuticals US, Inc.$99
  • Genentech USA, Inc.$90
  • Harmony Biosciences LLC$70
  • plus $258 from 7 others

What the payments were for

  • Food & beverage$75482%
  • Education$16518%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$919 in reported general payments places this provider in the 20th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$19,197
Medicare patients
43
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$25,130
Breo ElliptaFluticasone/Vilanterol22$9,075
Wixela InhubFluticasone Propion/Salmeterol59$8,030
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,720
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,599
Fluticasone Propionate HfaFluticasone Propionate18$4,529
Albuterol Sulfate HfaAlbuterol Sulfate99$4,247
LantusInsulin Glargine,hum.Rec.Anlog15$1,050
Levalbuterol Tartrate HfaLevalbuterol Tartrate17$970
Fluticasone Propionate50$760
Montelukast Sodium81$631
Dexamethasone28$610
Temazepam12$468
Azelastine Hcl12$213
Bupropion Hcl SrBupropion Hcl11$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$156$40,92572 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Humacao

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →